Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly increases Chinese sales by 26 per cent

Eli Lilly says its has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole

US-based pharmaceutical company Eli Lilly has said it has grown sales of its pharmaceutical products in China by 26 per cent, compared with sales over a year ago, with 16 per cent growth for the pharmaceutical industry in the region as a whole.

The company added that it expected to become the tenth largest company in the global pharmaceutical market by 2010. China is expected to become the seventh largest pharmaceutical market in 2012 and the second largest in 2020.

Lilly says it will introduce five drugs to the Chinese market in 2007 and an additional fifteen drugs over the next five years. The company signed an agreement with Hutchison Whampao, a drug development unit owned by Li Ka-shing, for the development of western drugs for treating cancer and inflammation.

18th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics